Hidetoshi Hayashi
0000-0001-8787-5587
Publication & Citation Trends
Publications
637 total
Immune evasion through mitochondrial transfer in the tumour microenvironment PDF
Cited by 210
OpenAlex
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC PDF
Cited by 349
OpenAlex
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial PDF
Cited by 271
OpenAlex
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy PDF
Cited by 212
OpenAlex
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Cited by 155
OpenAlex
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor PDF
Cited by 184
OpenAlex
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration PDF
Cited by 392
OpenAlex
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer
Cited by 238
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(401)
Lung Cancer Research Studies
(169)
Cancer Immunotherapy and Biomarkers
(161)
HER2/EGFR in Cancer Research
(130)
Colorectal Cancer Treatments and Studies
(87)
Affiliations
Hiroshima University
Harbin Medical University
Mie University
Mitsui Chemicals (Germany)
Nagoya City University